Q1 Earnings Estimate for DYN Issued By HC Wainwright

Dyne Therapeutics, Inc. (NASDAQ:DYN) – HC Wainwright issued their Q1 2026 earnings estimates for shares of Dyne Therapeutics in a research report issued to clients and investors on Tuesday, March 3rd. HC Wainwright analyst A. Ghosh expects that the company will post earnings of ($0.76) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q2 2026 earnings at ($0.76) EPS and Q3 2026 earnings at ($0.76) EPS.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

A number of other research analysts have also recently commented on the stock. Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday. Royal Bank Of Canada boosted their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday. Finally, Robert W. Baird set a $30.00 price target on Dyne Therapeutics in a research report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $15.23 on Thursday. The firm has a market cap of $2.51 billion, a PE ratio of -4.30 and a beta of 1.34. The company has a quick ratio of 13.47, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $25.00. The business’s fifty day simple moving average is $17.26 and its 200-day simple moving average is $17.04.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Dyne Therapeutics in the first quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after purchasing an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after buying an additional 366,183 shares in the last quarter. Caxton Associates LLP acquired a new stake in Dyne Therapeutics in the first quarter valued at $157,000. Finally, CWM LLC lifted its holdings in Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after buying an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.